Definitive Contract 75F40119C10129
Award Date
9/13/19
Potential Completion Date
9/15/21
Potential Value
$284K
Federal Agency
Food and Drug Administration
Ultimate Awardee
University Of Texas System
PSC Category
AN16 - R&D- Medical: Biomedical (Management/Support)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
34
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award made by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson), a component of the University of Texas System. The award, valued at $2,387,945.37, is for biomedical research and development activities, with an ultimate completion date of August 21, 2013. The contract is a definitive contract with a cost-no-fee pricing type, and does not have...
This is a three-year, $13,481,325.00 definitive contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract supports a Phase II chemoprevention clinical trial in patients with adenomatous polyposis coli, a genetic condition that increases cancer risk. The contract does not have a small business set-aside designation. MD Anderson Cancer Center, a comprehensive cancer research and...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a Firm Fixed Price Definitive Contract for $150,904.40 to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for an "Invasive Mold Data Acquisition" project. The contract does not have a set-aside designation and was awarded on July 15, 2019, with a completion date of July 14, 2020. MD Anderson Cancer Center is a comprehensive cancer treatment...
This is a delivery order issued under the National Cancer Institute's Cancer Prevention Agent Development Program 2012-2017 indefinite delivery/indefinite quantity (IDIQ) contract. The contract was awarded to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to provide core infrastructure support for the program. The award has a ceiling value of $725,737.89 and an ultimate completion date of September 23, 2015. The contract is a cost-no-fee type...
This is a $1,253,018.75 delivery order awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for the VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST. The contract is part of the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery contract. The award supports an early phase...
This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...
This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a...
This is a federal contract award from the National Heart Lung and Blood Institute, a component of the National Institutes of Health, to The University of Texas MD Anderson Cancer Center, a state-run hospital and research institution in Houston, Texas. The $8,039,555.77 definitive cost-reimbursement contract supports the Salivary Gland Tumor Biorepository (SGTB) program, which is focused on biomedical research related to salivary gland tumors. The contract has an ultimate completion date of...
This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...
This is a modification to a federal contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson). The original contract was a definitive cost-no-fee contract awarded on February 15, 2003 with a ceiling value of $8,606,292. This modification is to deobligate FY06 funds. MD Anderson, a U.S. state government entity and academic medical center, has been the prime contractor as...